Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2026
DOI: 10.1016/j.bbcan.2025.189517 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2026. Verfasst von Zilong Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepato-Pancreato-Biliary Surgery, Clinical Medical Research Center of Hepatic Surgery at Hubei Province, and Hubei Key Laboratory of Hepa…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Liver Cirrhosis, Immune Evasion. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 235 Literaturangaben. Gefördert von: Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan Municipal Health Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) arising on a background of fibrosis has fundamental mechanistic and clinical differences compared to HCC that arises in a non-fibrotic liver. The fibrotic microenvironment is characterized by extracellular matrix (ECM) remodeling, dynamic interactions with immune and stromal cells, and activation of hepatic stellate cells (HSCs) and cancer-associated fibroblasts (CAFs). Recent multi-omics analyses have demonstrated that these fibrotic niches dynamically promote hepatocarcinogenesis, metastasis and immune evasion. Several therapeutic strategies targeting fibrosis have improved HCC outcomes in clinical trials. These advances have facilitated an understanding of the complex mechanisms underlying fibrosis-driven HCC and are helping to optimize therapeutic prescriptions. This review synthesizes recent advances in understanding the role of fibrosis in hepatocarcinogenesis, aggressiveness, and metastasis; decodes how stromal-immune crosstalk defines immune escape through the fibrosis-driven '3C' immune evasion framework; and links mechanistic insights into fibrosis-driven HCC with emerging theranostic strategies. We emphasize that targeting fibrosis-driven oncogenic mechanisms may enhance the therapeutic efficacy in HCC, thus providing a scientific foundation for rationalizing this approach as a viable strategy against both liver fibrosis and HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hepato-Pancreato-Biliary Surgery, Clinical Medical Research Center of Hepatic Surgery at Hubei Province, and Hubei Key Laboratory of Hepato-Pancreatic-Biliary Diseases, Tongji Hospital, Tongji Medical Colleg…
Förderung
- Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
- Wuhan Municipal Health Commission
- National Natural Science Foundation of China
- Huazhong University of Science and Technology
Zitieren
APA
Zhang, Z., Chen, X., Zhang, B., Zhang, W., Ding, Z. Y., Expert Group on Portal Hypertension of the Chinese College of Surgeons (CCS), & Chinese Medical Doctor Association (CMDA) (2026). Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2025.189517
Vancouver
Zhang Z, Chen X, Zhang B, Zhang W, Ding ZY, Expert Group on Portal Hypertension of the Chinese College of Surgeons (CCS), et al. Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2026. doi:10.1016/j.bbcan.2025.189517
BibTeX
@article{Zhang2026,
author = {Zhang, Zilong and Chen, Xiaoping and Zhang, Bixiang and Zhang, Wanguang and Ding, Ze-Yang and Expert Group on Portal Hypertension of the Chinese College of Surgeons (CCS), Expert Group on Portal Hypertension of the Chinese College of Surgeons (CCS) and Chinese Medical Doctor Association (CMDA), Chinese Medical Doctor Association (CMDA)},
title = {Fibrosis-driven hepatocarcinogenesis, metastasis and immune evasion: Mechanisms and therapeutic targets},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2026},
doi = {10.1016/j.bbcan.2025.189517}
}
EUVIMED